[148] have highlighted the neuropsychiatric dimensions of GLP-1 RAs, including their potential relevance for relapse vulnerability and cognitive-affective regulation after pharmacotherapy discontinuation
References and Clinical Evidence Extensive peer reviewed research supports the efficacy and safety profiles of these growth hormone releasing peptides across multiple research applications
learning memory and exploration behavior are impaired, oxidative stress factor expression is changed, and mitochondria are damaged
One study from February 2025, for instance, suggests that people who take glucagon-like peptide-1 receptor agonist medication like Ozempic to treat diabetes have a lower depression risk than peers taking other types of drugs for this metabolic condition
Sermorelin's clinical rationale is grounded in its role as a growth hormone-releasing hormone (GHRH) analog, which stimulates the pituitary to support the body's natural production of growth hormone
This is because prolonged exposure to the drug can lead to cumulative effects on your skin